A Close Call: FDA’s Decision Memo On The Approval of Chelsea Therapeutics’ Northera
This article was originally published in RPM Report
On February 18, FDA granted accelerated approval to Chelsea Therapeutics’ Northera (droxidopa) for neurogenic orthostatic hypotension. The review was difficult, generating a “complete response” letter and a formal dispute resolution after the first cycle, and a negative primary review on the second go-around. The final decision by Office of Drug Evaluation I Director Ellis Unger was to overrule the division director and approve the application. His approval memo stands out for its detailed analysis of the arguments “pro” and “con,” and ultimately as a statement in support of extra flexibility for rare disease drugs. Here is the conclusion of his memo.
You may also be interested in...
Advisory committee members say they’d feel better about approving combo products for hypertension if labeling included pivotal trial data enabling clinicians to assess how individual patients fared on therapy.
Northera was approved by FDA under the Subpart H accelerated approval pathway; the Indications and Usage section of the drug’s labeling notes the lack of efficacy data for treatment with the drug beyond two weeks.
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.